Review

mouse anti human ccl20 (R&D Systems)

R&D Systems is a verified supplier

R&D Systems manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

R&D Systems mouse anti human ccl20

A Bulk sequencing data from TCGA (left) and GTEx (right) showing <t>CCL20</t> expression. Gastrointestinal tissues prominently express CCL20 while other epithelial tissues expressed little if any CCL20. B Expression of CCL20 by the different cell types found in primary tumors from a PDAC scRNA atlas . C CCL20 expression from a scRNA dataset healthy human colon (H) and colorectal cancer . D Expression of CCL20 by different cells found in a single nucleus RNA sequencing dataset of chronic pancreatitis biopsies . E CCR6, CCL20, IL-17A, and IL-23A in a scRNA datasets of CD45+ cells from human chronic pancreatitis or healthy patients . Pancreatitis was classified as hereditary if there were mutations present in PRSS1 gene. F Expression of CCL20 in a scRNA dataset of human ulcerative colitis (UC) and Crohn’s disease (CD) . G Differentially expressed chemokines found using MAST from a scRNA atlas of PDAC .

Mouse Anti Human Ccl20, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 24 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse anti human ccl20/product/R&D Systems
Average 93 stars, based on 24 article reviews

mouse anti human ccl20 - by Bioz Stars, 2026-06

93/100 stars

Images

1) Product Images from "Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma"

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

Journal: bioRxiv

doi: 10.64898/2026.04.13.717530

A Bulk sequencing data from TCGA (left) and GTEx (right) showing CCL20 expression. Gastrointestinal tissues prominently express CCL20 while other epithelial tissues expressed little if any CCL20. B Expression of CCL20 by the different cell types found in primary tumors from a PDAC scRNA atlas . C CCL20 expression from a scRNA dataset healthy human colon (H) and colorectal cancer . D Expression of CCL20 by different cells found in a single nucleus RNA sequencing dataset of chronic pancreatitis biopsies . E CCR6, CCL20, IL-17A, and IL-23A in a scRNA datasets of CD45+ cells from human chronic pancreatitis or healthy patients . Pancreatitis was classified as hereditary if there were mutations present in PRSS1 gene. F Expression of CCL20 in a scRNA dataset of human ulcerative colitis (UC) and Crohn’s disease (CD) . G Differentially expressed chemokines found using MAST from a scRNA atlas of PDAC .

Figure Legend Snippet: A Bulk sequencing data from TCGA (left) and GTEx (right) showing CCL20 expression. Gastrointestinal tissues prominently express CCL20 while other epithelial tissues expressed little if any CCL20. B Expression of CCL20 by the different cell types found in primary tumors from a PDAC scRNA atlas . C CCL20 expression from a scRNA dataset healthy human colon (H) and colorectal cancer . D Expression of CCL20 by different cells found in a single nucleus RNA sequencing dataset of chronic pancreatitis biopsies . E CCR6, CCL20, IL-17A, and IL-23A in a scRNA datasets of CD45+ cells from human chronic pancreatitis or healthy patients . Pancreatitis was classified as hereditary if there were mutations present in PRSS1 gene. F Expression of CCL20 in a scRNA dataset of human ulcerative colitis (UC) and Crohn’s disease (CD) . G Differentially expressed chemokines found using MAST from a scRNA atlas of PDAC .

Techniques Used: Sequencing, Expressing, RNA Sequencing

A Representative PCR analyses of CCL20 and CCR6 transcript expression across multiple human and B mouse PDAC cell lines. Data representative of 3 individual analyses. C Quantification of the CCL20 staining images. 3-7 fields of view were quantified per patient, with five patients per disease state . D Representative immunostaining for CCL20 (red) or DAPI-stained cell nuclei (blue) (top) with parallel sections stained with H&E (bottom) in both healthy human pancreas or E human PDAC samples. * denotes p ≤ 0.05, Student’s unpaired t-test. Size bar = 100 μm.

Figure Legend Snippet: A Representative PCR analyses of CCL20 and CCR6 transcript expression across multiple human and B mouse PDAC cell lines. Data representative of 3 individual analyses. C Quantification of the CCL20 staining images. 3-7 fields of view were quantified per patient, with five patients per disease state . D Representative immunostaining for CCL20 (red) or DAPI-stained cell nuclei (blue) (top) with parallel sections stained with H&E (bottom) in both healthy human pancreas or E human PDAC samples. * denotes p ≤ 0.05, Student’s unpaired t-test. Size bar = 100 μm.

Techniques Used: Expressing, Staining, Immunostaining

A Gene sets listed in Supplementary Data 7 were correlated with CCL20 expression in ductal cells from a scRNA dataset of human PDAC and B colorectal cancer . Values shown are Pearson’s correlation coefficients, all p values = 0. C TCGA PDAC patients and D colorectal cancer patients sorted by SBS1 (replicative age) signatures, with comparisons of their normalized CCL20 expression. E TCGA PDAC patients sorted by their CN1 (diploid) and F CN2 (tetraploid) signatures using data from previously reported . Similar analysis for colorectal cancer patients can be seen in G and H . I Normalized CCL20 methylation values (probe cg21643045) from all GI cancers (cancer types in the top row of ) sorted by CCL20 expression. J CCL20 high patients (relative to patients of same cancer type) with their CCL20 normalized methylation values plotted. Non-GI mucosal cancers are bladder, cervical, head and neck, both lung types, and both uterine tumor types. Panel C-I Student’s unpaired t -test was used with p values plotted. Panel J one-way ANOVA with Tukey’s test for multiple comparisons, * denotes p ≤ 0.05.

Figure Legend Snippet: A Gene sets listed in Supplementary Data 7 were correlated with CCL20 expression in ductal cells from a scRNA dataset of human PDAC and B colorectal cancer . Values shown are Pearson’s correlation coefficients, all p values = 0. C TCGA PDAC patients and D colorectal cancer patients sorted by SBS1 (replicative age) signatures, with comparisons of their normalized CCL20 expression. E TCGA PDAC patients sorted by their CN1 (diploid) and F CN2 (tetraploid) signatures using data from previously reported . Similar analysis for colorectal cancer patients can be seen in G and H . I Normalized CCL20 methylation values (probe cg21643045) from all GI cancers (cancer types in the top row of ) sorted by CCL20 expression. J CCL20 high patients (relative to patients of same cancer type) with their CCL20 normalized methylation values plotted. Non-GI mucosal cancers are bladder, cervical, head and neck, both lung types, and both uterine tumor types. Panel C-I Student’s unpaired t -test was used with p values plotted. Panel J one-way ANOVA with Tukey’s test for multiple comparisons, * denotes p ≤ 0.05.

Techniques Used: Expressing, Methylation

A The top three transcription factors inferred using CollecTRI from all pancreatic exocrine ductal cells in a single cell RNA dataset sorted by CCL20 expression. B Inferred transcription factors from tumor cells from a CRC dataset sorted by CCL20 expression. C qPCR and D ELISA for CCL20 transcript expression and protein secretion by human PANC-1 cell line. E qPCR for CXCL2 by the PANC-1 cell line. ND = not detected by qPCR. ns, not significant. F qPCR for CCL20 and G CXCL2 expression by the patient-derived 339 cell line possessing a KRAS G12V mutation. H qPCR and I ELISA for CCL20 in the murine KPC FC1242 stably expressing Firefly luciferase PDAC cell line. Treatments were for 24 hours. Concentrations of the individual treatments were: Erlotinib 500 nM, regorafenib 500 nM, MRTX1133 500 nM, gemcitabine 100 nM, TNF 20 ng/mL with 10 ng/mL of IL-1, and RMC-7977 300 nM. For resistant cell lines (denoted by -R), resistance was considered established when cells survived in full growth medium supplemented with 10 μM of the denoted chemotherapy drug. One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line.

Figure Legend Snippet: A The top three transcription factors inferred using CollecTRI from all pancreatic exocrine ductal cells in a single cell RNA dataset sorted by CCL20 expression. B Inferred transcription factors from tumor cells from a CRC dataset sorted by CCL20 expression. C qPCR and D ELISA for CCL20 transcript expression and protein secretion by human PANC-1 cell line. E qPCR for CXCL2 by the PANC-1 cell line. ND = not detected by qPCR. ns, not significant. F qPCR for CCL20 and G CXCL2 expression by the patient-derived 339 cell line possessing a KRAS G12V mutation. H qPCR and I ELISA for CCL20 in the murine KPC FC1242 stably expressing Firefly luciferase PDAC cell line. Treatments were for 24 hours. Concentrations of the individual treatments were: Erlotinib 500 nM, regorafenib 500 nM, MRTX1133 500 nM, gemcitabine 100 nM, TNF 20 ng/mL with 10 ng/mL of IL-1, and RMC-7977 300 nM. For resistant cell lines (denoted by -R), resistance was considered established when cells survived in full growth medium supplemented with 10 μM of the denoted chemotherapy drug. One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line.

Techniques Used: Single Cell, Expressing, Enzyme-linked Immunosorbent Assay, Derivative Assay, Mutagenesis, Stable Transfection, Luciferase

A Mean fluorescence intensity (MFI) of anti-phospho-p65-PE immunostained FC1245 and RMC-7977 (2 μM)-resistant FC1245 PDAC cells. * denotes p ≤ 0.05, Student’s unpaired t -test. B Expression of CCL20 in a single cell RNA dataset of pancreatic ductal cells obtained from mice with a Ptf1a specific tamoxifen inducible Kras -G12D. The time listed on the y-axis is time from when the initial tamoxifen was given. C The number of wild-type C57BL6 splenocytes migrated in a chemotaxis assay using conditioned media from the listed FC1242 PDAC cell line. The conditioned media was obtained from cells outlined in . One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line D Treatment schema for mice treated implanted with orthotopic KPC1199 tumors and treated with either vehicle PBS or 100 μg CCL20LD. E The mass of the tumors from the experiment outlined in . F CD11c+ MHCII+ dendritic cells, G CD11b+ F4/80+ macrophages, and H MHCII high macrophages (as a percentage of macrophages) in the harvested tumors. * denotes p ≤ 0.05, Student’s unpaired t -test.

Figure Legend Snippet: A Mean fluorescence intensity (MFI) of anti-phospho-p65-PE immunostained FC1245 and RMC-7977 (2 μM)-resistant FC1245 PDAC cells. * denotes p ≤ 0.05, Student’s unpaired t -test. B Expression of CCL20 in a single cell RNA dataset of pancreatic ductal cells obtained from mice with a Ptf1a specific tamoxifen inducible Kras -G12D. The time listed on the y-axis is time from when the initial tamoxifen was given. C The number of wild-type C57BL6 splenocytes migrated in a chemotaxis assay using conditioned media from the listed FC1242 PDAC cell line. The conditioned media was obtained from cells outlined in . One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line D Treatment schema for mice treated implanted with orthotopic KPC1199 tumors and treated with either vehicle PBS or 100 μg CCL20LD. E The mass of the tumors from the experiment outlined in . F CD11c+ MHCII+ dendritic cells, G CD11b+ F4/80+ macrophages, and H MHCII high macrophages (as a percentage of macrophages) in the harvested tumors. * denotes p ≤ 0.05, Student’s unpaired t -test.

Techniques Used: Fluorescence, Expressing, Single Cell, Chemotaxis Assay

A Graphical abstract summarizing the findings. CCL20 is not expressed in the healthy pancreas. In pancreatitis, it is expressed the lymphocytic infiltrate. In PanINs, CCL20 begins to be expressed by the ductal epithelium. In PDAC, CCL20 expression is further increased by the ductal tumor cells and infiltrating myeloid cells. CCL20 expression is lost with resistance to KRAS inhibitors, along with decreased phosphorylation of RELA , and is limited to the basal subtype. Inhibition of CCL20-CCR6 signaling increased levels of antigen presenting cells, including dendritic cells and MHCII-high macrophages within the tumor parenchyma.

Figure Legend Snippet: A Graphical abstract summarizing the findings. CCL20 is not expressed in the healthy pancreas. In pancreatitis, it is expressed the lymphocytic infiltrate. In PanINs, CCL20 begins to be expressed by the ductal epithelium. In PDAC, CCL20 expression is further increased by the ductal tumor cells and infiltrating myeloid cells. CCL20 expression is lost with resistance to KRAS inhibitors, along with decreased phosphorylation of RELA , and is limited to the basal subtype. Inhibition of CCL20-CCR6 signaling increased levels of antigen presenting cells, including dendritic cells and MHCII-high macrophages within the tumor parenchyma.

Techniques Used: Expressing, Phospho-proteomics, Inhibition

Image Search Results

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A Bulk sequencing data from TCGA (left) and GTEx (right) showing CCL20 expression. Gastrointestinal tissues prominently express CCL20 while other epithelial tissues expressed little if any CCL20. B Expression of CCL20 by the different cell types found in primary tumors from a PDAC scRNA atlas . C CCL20 expression from a scRNA dataset healthy human colon (H) and colorectal cancer . D Expression of CCL20 by different cells found in a single nucleus RNA sequencing dataset of chronic pancreatitis biopsies . E CCR6, CCL20, IL-17A, and IL-23A in a scRNA datasets of CD45+ cells from human chronic pancreatitis or healthy patients . Pancreatitis was classified as hereditary if there were mutations present in PRSS1 gene. F Expression of CCL20 in a scRNA dataset of human ulcerative colitis (UC) and Crohn’s disease (CD) . G Differentially expressed chemokines found using MAST from a scRNA atlas of PDAC .

Article Snippet: Samples were deparaffinized, blocked with 2% (v/v) goat serum (ThermoFisher #31872), stained with mouse anti-human CCL20 (R&D systems MAB360) at a concentration of 1:100 and goat anti-mouse IgG Alexa fluor 647 (ThermoFisher #A48289) at a concentration of 1:500.

Techniques: Sequencing, Expressing, RNA Sequencing

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A Representative PCR analyses of CCL20 and CCR6 transcript expression across multiple human and B mouse PDAC cell lines. Data representative of 3 individual analyses. C Quantification of the CCL20 staining images. 3-7 fields of view were quantified per patient, with five patients per disease state . D Representative immunostaining for CCL20 (red) or DAPI-stained cell nuclei (blue) (top) with parallel sections stained with H&E (bottom) in both healthy human pancreas or E human PDAC samples. * denotes p ≤ 0.05, Student’s unpaired t-test. Size bar = 100 μm.

Techniques: Expressing, Staining, Immunostaining

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A Gene sets listed in Supplementary Data 7 were correlated with CCL20 expression in ductal cells from a scRNA dataset of human PDAC and B colorectal cancer . Values shown are Pearson’s correlation coefficients, all p values = 0. C TCGA PDAC patients and D colorectal cancer patients sorted by SBS1 (replicative age) signatures, with comparisons of their normalized CCL20 expression. E TCGA PDAC patients sorted by their CN1 (diploid) and F CN2 (tetraploid) signatures using data from previously reported . Similar analysis for colorectal cancer patients can be seen in G and H . I Normalized CCL20 methylation values (probe cg21643045) from all GI cancers (cancer types in the top row of ) sorted by CCL20 expression. J CCL20 high patients (relative to patients of same cancer type) with their CCL20 normalized methylation values plotted. Non-GI mucosal cancers are bladder, cervical, head and neck, both lung types, and both uterine tumor types. Panel C-I Student’s unpaired t -test was used with p values plotted. Panel J one-way ANOVA with Tukey’s test for multiple comparisons, * denotes p ≤ 0.05.

Techniques: Expressing, Methylation

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A The top three transcription factors inferred using CollecTRI from all pancreatic exocrine ductal cells in a single cell RNA dataset sorted by CCL20 expression. B Inferred transcription factors from tumor cells from a CRC dataset sorted by CCL20 expression. C qPCR and D ELISA for CCL20 transcript expression and protein secretion by human PANC-1 cell line. E qPCR for CXCL2 by the PANC-1 cell line. ND = not detected by qPCR. ns, not significant. F qPCR for CCL20 and G CXCL2 expression by the patient-derived 339 cell line possessing a KRAS G12V mutation. H qPCR and I ELISA for CCL20 in the murine KPC FC1242 stably expressing Firefly luciferase PDAC cell line. Treatments were for 24 hours. Concentrations of the individual treatments were: Erlotinib 500 nM, regorafenib 500 nM, MRTX1133 500 nM, gemcitabine 100 nM, TNF 20 ng/mL with 10 ng/mL of IL-1, and RMC-7977 300 nM. For resistant cell lines (denoted by -R), resistance was considered established when cells survived in full growth medium supplemented with 10 μM of the denoted chemotherapy drug. One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line.

Techniques: Single Cell, Expressing, Enzyme-linked Immunosorbent Assay, Derivative Assay, Mutagenesis, Stable Transfection, Luciferase

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A Mean fluorescence intensity (MFI) of anti-phospho-p65-PE immunostained FC1245 and RMC-7977 (2 μM)-resistant FC1245 PDAC cells. * denotes p ≤ 0.05, Student’s unpaired t -test. B Expression of CCL20 in a single cell RNA dataset of pancreatic ductal cells obtained from mice with a Ptf1a specific tamoxifen inducible Kras -G12D. The time listed on the y-axis is time from when the initial tamoxifen was given. C The number of wild-type C57BL6 splenocytes migrated in a chemotaxis assay using conditioned media from the listed FC1242 PDAC cell line. The conditioned media was obtained from cells outlined in . One-way ANOVA was used for statistical analysis with Dunnett’s test for multiple comparisons used to compare to the untreated cell line D Treatment schema for mice treated implanted with orthotopic KPC1199 tumors and treated with either vehicle PBS or 100 μg CCL20LD. E The mass of the tumors from the experiment outlined in . F CD11c+ MHCII+ dendritic cells, G CD11b+ F4/80+ macrophages, and H MHCII high macrophages (as a percentage of macrophages) in the harvested tumors. * denotes p ≤ 0.05, Student’s unpaired t -test.

Techniques: Fluorescence, Expressing, Single Cell, Chemotaxis Assay

Journal: bioRxiv

Article Title: Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma

doi: 10.64898/2026.04.13.717530

Figure Lengend Snippet: A Graphical abstract summarizing the findings. CCL20 is not expressed in the healthy pancreas. In pancreatitis, it is expressed the lymphocytic infiltrate. In PanINs, CCL20 begins to be expressed by the ductal epithelium. In PDAC, CCL20 expression is further increased by the ductal tumor cells and infiltrating myeloid cells. CCL20 expression is lost with resistance to KRAS inhibitors, along with decreased phosphorylation of RELA , and is limited to the basal subtype. Inhibition of CCL20-CCR6 signaling increased levels of antigen presenting cells, including dendritic cells and MHCII-high macrophages within the tumor parenchyma.

Techniques: Expressing, Phospho-proteomics, Inhibition

Effect of CITED2 silencing on the expression of macrophage chemotactic factors. mRNA expression in (A) orthotopic xenograft tumors and (B) cells in culture, as determined by reverse transcription-quantitative polymerase chain reaction. (C) Protein expression in the two groups, as determined by ELISA. (D) Localization of CITED2 to the CCL20 promoter, as assessed by a chromatin immunoprecipitation assay using anti-CITED2 or IgG antibodies (control) in MDA-MB-231 and MDA-MB-468 cells. *P<0.05; **P<0.01; ***P<0.001 vs. scramble group (A-C) and vs. IgG (D). CITED2, Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain-2; sh, short hairpin; CCL, C-C motif chemokine ligand; Ig, immunoglobulin; IL, interleukin; CX3CL, C-X3-C motif chemokine ligand.

Journal: Oncology Letters

Article Title: CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells

doi: 10.3892/ol.2017.7420

Figure Lengend Snippet: Effect of CITED2 silencing on the expression of macrophage chemotactic factors. mRNA expression in (A) orthotopic xenograft tumors and (B) cells in culture, as determined by reverse transcription-quantitative polymerase chain reaction. (C) Protein expression in the two groups, as determined by ELISA. (D) Localization of CITED2 to the CCL20 promoter, as assessed by a chromatin immunoprecipitation assay using anti-CITED2 or IgG antibodies (control) in MDA-MB-231 and MDA-MB-468 cells. *P<0.05; **P<0.01; ***P<0.001 vs. scramble group (A-C) and vs. IgG (D). CITED2, Cbp/p300-interacting transactivator with Glu/Asp-rich carboxy-terminal domain-2; sh, short hairpin; CCL, C-C motif chemokine ligand; Ig, immunoglobulin; IL, interleukin; CX3CL, C-X3-C motif chemokine ligand.

Article Snippet: For CCL20 neutralization, mouse anti-human CCL20 antibody (cat. no. MAB360; dilution, 1:165; R&D Systems, Inc., Minneapolis, MN, USA) or non-specific mouse immunoglobulin G (IgG; cat. no. MAB002; dilution, 1:165; R&D Systems, Inc.) was added to the conditioned medium of wild-type MDA-MB-231 cells.

Techniques: Expressing, Reverse Transcription, Real-time Polymerase Chain Reaction, Enzyme-linked Immunosorbent Assay, Chromatin Immunoprecipitation, Control

Effect of inhibiting CCL20 on the induction of macrophage recruitment by MDA-MB-231 cell-conditioned media. Top: Representative images revealed macrophage recruitment by in vitro Transwell migration assay. Bottom: Quantification of the average number of macrophages recruited per experimental condition. ***P<0.001. Magnification, ×400. CCL, C-C motif chemokine ligand; Ig, immunoglobulin; neu, neutral.

Journal: Oncology Letters

Article Title: CITED2 attenuates macrophage recruitment concordant with the downregulation of CCL20 in breast cancer cells

doi: 10.3892/ol.2017.7420

Figure Lengend Snippet: Effect of inhibiting CCL20 on the induction of macrophage recruitment by MDA-MB-231 cell-conditioned media. Top: Representative images revealed macrophage recruitment by in vitro Transwell migration assay. Bottom: Quantification of the average number of macrophages recruited per experimental condition. ***P<0.001. Magnification, ×400. CCL, C-C motif chemokine ligand; Ig, immunoglobulin; neu, neutral.

Techniques: In Vitro, Transwell Migration Assay

Astrocyte activity was measure with GFAP immunofluorescence. Representative photomicrographs show control and LPS-injected rats at different time points up to day 30. (A) Densitometry of GFAP fluorescence intensity was up-regulated from day 1 to day 7. Following LPS injection, astrocytes showed changes in morphology, which was recognized by decreased ramification and hypertrophy of the soma. (B) Double fluorescence staining of GFAP and TNF-α in hippocampal astrocytes. The ratio of TNF-α positive astrocytes in total astrocytes (GFAP-positive cells) was significantly increased from day 1 and peaking on day 7. Pictures show DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, **p<0.01, ***p<0.001 vs Control.

Journal: PLoS ONE

Article Title: Prolonged Neuroinflammation after Lipopolysaccharide Exposure in Aged Rats

doi: 10.1371/journal.pone.0106331

Figure Lengend Snippet: Astrocyte activity was measure with GFAP immunofluorescence. Representative photomicrographs show control and LPS-injected rats at different time points up to day 30. (A) Densitometry of GFAP fluorescence intensity was up-regulated from day 1 to day 7. Following LPS injection, astrocytes showed changes in morphology, which was recognized by decreased ramification and hypertrophy of the soma. (B) Double fluorescence staining of GFAP and TNF-α in hippocampal astrocytes. The ratio of TNF-α positive astrocytes in total astrocytes (GFAP-positive cells) was significantly increased from day 1 and peaking on day 7. Pictures show DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, **p<0.01, ***p<0.001 vs Control.

Article Snippet: Sections were then incubated with primary antibodies overnight at 4°C: goat anti-TNF-α IgG (1:100; catalog number AF-510-NA, R&D, Systems, Inc., Minneapolis, MN, USA), goat anti-IL-1β IgG (1:100; catalog number AF-501-NA, R&D, Systems, Inc., Minneapolis, MN, USA), rabbit anti-NF-kB p65 IgG (1:100; catalog number Ab7970, Abcam, Cambridge, MA, UAS), and mouse anti-Glial fibrillary acidic protein (GFAP) IgG (1:1000; catalog number MAB360 Millipore, Billerica, MA, USA) respectively.

Techniques: Activity Assay, Immunofluorescence, Control, Injection, Fluorescence, Staining

IL-1β immunoreactivity was measured in GFAP-positive cells after LPS exposure or saline. Levels of IL-1β were found up-regulated from day 1 up to day 30. Higher magnification insets highlight the co-localization of IL-1β with GFAP (A). The ratio of IL-1β positive astrocytes in total astrocytes (GFAP positive cells) was quantified (B). Pictures show DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, **p<0.01, ***p<0.001 vs Control.

Journal: PLoS ONE

Article Title: Prolonged Neuroinflammation after Lipopolysaccharide Exposure in Aged Rats

doi: 10.1371/journal.pone.0106331

Figure Lengend Snippet: IL-1β immunoreactivity was measured in GFAP-positive cells after LPS exposure or saline. Levels of IL-1β were found up-regulated from day 1 up to day 30. Higher magnification insets highlight the co-localization of IL-1β with GFAP (A). The ratio of IL-1β positive astrocytes in total astrocytes (GFAP positive cells) was quantified (B). Pictures show DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, **p<0.01, ***p<0.001 vs Control.

Techniques: Saline, Control

NF-κB activation in astrocytes was measured by NF-κB p65/GFAP double staining. Confocal images and quantification show a gradual increase in NF-κB p65 activity and nuclear translocation from day 1 to day 7, with a peak on day 3. Representative high magnification pictures are shown in the insets. Pictures are representative from DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, ***p<0.001 vs Control.

Journal: PLoS ONE

Article Title: Prolonged Neuroinflammation after Lipopolysaccharide Exposure in Aged Rats

doi: 10.1371/journal.pone.0106331

Figure Lengend Snippet: NF-κB activation in astrocytes was measured by NF-κB p65/GFAP double staining. Confocal images and quantification show a gradual increase in NF-κB p65 activity and nuclear translocation from day 1 to day 7, with a peak on day 3. Representative high magnification pictures are shown in the insets. Pictures are representative from DG area, data are expressed as mean ± standard error of the mean (n = 4) and compared by 1-way analysis of variance followed with Boferroni post hoc analysis, ***p<0.001 vs Control.

Techniques: Activation Assay, Double Staining, Activity Assay, Translocation Assay, Control

Review

Structured Review

Images

1) Product Images from "Mutant KRAS promotes NF-κB driven CCL20 chemokine expression in pancreatic ductal adenocarcinoma"

Similar Products

Image Search Results